De novo MET amplification (primary MET amplification) occurs in about 1-5% of non-small-cell lung cancers (NSCLC), and acquired MET amplification (secondary MET amplification) are typically identified in about 5-20% patients with oncogene-positive NSCLC following resistance to tyrosine kinase inhibitors (TKIs), such as EGFR TKIs (38, 39). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.